Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord

Area of Science:

• Neuroscience
• Gene Therapy
• Parkinson's Disease Research

Background:

• Parkinson's disease (PD) lacks effective disease-modifying therapies.
• Alpha-synuclein pathology may originate in the enteric nervous system (ENS) or autonomic nervous system in some PD patients.
• Targeting alpha-synuclein in the ENS offers a strategy to prevent early PD progression.

Purpose of the Study:

• To evaluate if anti-alpha-synuclein shRNA-minicircles (MC) delivered via RVG-engineered extracellular vesicles (RVG-EV) can decrease alpha-synuclein expression in the intestine and spinal cord.
• To assess the therapeutic potential of this approach in a preclinical model of Parkinson's disease.

Main Methods:

• Intravenous injection of RVG-EV containing anti-alpha-synuclein shRNA-MC into a PD mouse model.
• Quantification of alpha-synuclein downregulation using qPCR and Western blot in the intestine and spinal cord.
• Evaluation of treatment efficacy after pathology development and assessment of multidose requirements.

Main Results:

• Confirmed significant downregulation of alpha-synuclein in both the intestine and spinal cord of treated mice.
• Demonstrated that the therapy is effective in reducing alpha-synuclein expression in the brain, intestine, and spinal cord even after pathology onset.
• Indicated that a multidose regimen is necessary for sustained long-term alpha-synuclein downregulation.

Conclusions:

• Anti-alpha-synuclein shRNA-MC delivered by RVG-EV show promise as a therapeutic strategy for Parkinson's disease.
• This approach may delay or halt PD pathology progression by targeting alpha-synuclein in the peripheral and central nervous systems.
• Further research into multidose strategies is warranted for long-term therapeutic benefit.